Acetyl-ATF5 (K29) Antibody

What is ATF5 and why is its acetylation at K29 significant?

ATF5 is a member of the ATF/CREB family of transcription factors that regulates cell proliferation, survival, and differentiation. Acetylation at lysine-29 (K29) is a critical post-translational modification that occurs in a p300-dependent manner. This specific acetylation enhances the interaction between ATF5 and p300, promoting binding of the ATF5/p300 complex to the ATF5 response element (ARE) in target gene promoters. This modification is essential for ATF5-dependent gene expression regulation, particularly for genes involved in cell proliferation and survival pathways . The acetylation stabilizes ATF5/p300 complex formation, allowing it to function as a transcriptional activator that regulates downstream targets such as Egr-1 .

What cellular processes are regulated by acetylated ATF5?

Acetylated ATF5 at K29 regulates several critical cellular processes:

• Cell proliferation and survival: Through activation of genes like Egr-1, acetylated ATF5 promotes cell proliferation and prevents apoptosis, particularly in cancer cells .

• Adipocyte differentiation: Acetylated ATF5 can directly interact with C/EBPβ through p300-dependent acetylation and bind to the C/EBPα promoter, enhancing C/EBPβ transactivation of C/EBPα, a key regulator of adipocyte differentiation .

• Tumor progression: In glioblastoma and breast cancer, p300-acetylated ATF5 regulates tumorigenesis and progression .

• Response to cellular stress: Acetylated ATF5 participates in stress response pathways, with serum deprivation disrupting the interaction between ATF5 and p300, decreasing ATF5 acetylation levels .

How does the Acetyl-ATF5 (K29) antibody differ from general ATF5 antibodies?

The Acetyl-ATF5 (K29) antibody specifically recognizes ATF5 only when acetylated at the lysine-29 residue, unlike general ATF5 antibodies that detect the protein regardless of its acetylation status. This specificity allows researchers to:

• Distinguish between acetylated and non-acetylated forms of ATF5

• Monitor p300-dependent acetylation activity on ATF5

• Study specific pathways dependent on ATF5 acetylation at K29

• Track changes in ATF5 acetylation status under different cellular conditions

The antibody is typically generated using a synthetic peptide derived from human ATF5 surrounding the acetylation site at K29, ensuring high specificity for this particular post-translational modification .

What are the validated applications for Acetyl-ATF5 (K29) antibodies?

Based on the available data, the validated applications for Acetyl-ATF5 (K29) antibodies include:

The antibody is typically affinity-purified from rabbit antiserum using epitope-specific immunogen chromatography to ensure specificity and reduce background .

How should researchers design experiments to study p300-dependent ATF5 acetylation?

When designing experiments to study p300-dependent ATF5 acetylation, consider the following methodological approach:

• Validation of acetylation status:

  • Transfect cells with wild-type ATF5, ATF5(K29R) mutant (where K29 is mutated to arginine), and p300 expression vectors

  • Perform immunoprecipitation with ATF5 antibody followed by Western blotting with Acetyl-ATF5 (K29) antibody

  • Include appropriate controls: ATF5(K29R) mutant should show no acetylation signal

• Manipulation of p300 activity:

  • Use p300/CBP inhibitors such as anacardic acid or garcinol to block acetyltransferase activity

  • Employ siRNA-mediated knockdown of p300/CBP

  • Treat cells with trichostatin A (TSA), a histone deacetylase inhibitor, to enhance acetylation

• Functional analysis:

  • Perform chromatin immunoprecipitation (ChIP) assays to assess binding of acetylated ATF5 to target promoters

  • Use luciferase reporter assays with wild-type and mutant promoters to evaluate transcriptional activity

  • Compare the effects of wild-type ATF5 versus ATF5(K29R) on target gene expression

• Cellular context consideration:

  • Study the effects of serum deprivation, which has been shown to disrupt ATF5-p300 interaction

  • Evaluate the effect of growth factors (e.g., EGF) on ATF5 acetylation and downstream signaling

What controls should be included when using Acetyl-ATF5 (K29) antibody in Western blot experiments?

To ensure reliable and interpretable results when using Acetyl-ATF5 (K29) antibody in Western blot experiments, include these essential controls:

• Positive controls:

  • Lysates from cells overexpressing wild-type ATF5 and p300

  • Samples treated with histone deacetylase inhibitors (e.g., trichostatin A) to enhance acetylation signals

  • Recombinant acetylated ATF5 protein (if available)

• Negative controls:

  • Lysates from cells expressing ATF5(K29R) mutant (cannot be acetylated at K29)

  • Samples from p300/CBP-depleted cells (by siRNA knockdown)

  • Samples treated with p300/CBP inhibitors (e.g., anacardic acid or garcinol)

• Specificity controls:

  • Peptide competition assay using the acetylated immunogenic peptide

  • Deacetylation of samples using recombinant histone deacetylases prior to immunoblotting

  • Parallel blotting with general ATF5 antibody to compare total protein levels

• Loading and transfer controls:

  • Probing for housekeeping proteins (β-actin, GAPDH)

  • Ponceau S staining of the membrane to verify uniform protein transfer

How can researchers investigate the interplay between ATF5 acetylation and other post-translational modifications?

Investigating the interplay between ATF5 acetylation and other post-translational modifications requires sophisticated experimental approaches:

• Sequential immunoprecipitation technique:

  • First immunoprecipitate with Acetyl-ATF5 (K29) antibody

  • Then probe for other modifications (phosphorylation, ubiquitination) using specific antibodies

  • Alternatively, immunoprecipitate with antibodies against other modifications and then detect acetylation status

• Mass spectrometry analysis:

  • Perform tandem mass spectrometry on immunoprecipitated ATF5 to identify all modifications simultaneously

  • Use SILAC (Stable Isotope Labeling with Amino acids in Cell culture) to quantitatively compare modification patterns under different conditions

• Site-directed mutagenesis approach:

  • Generate ATF5 mutants lacking specific modification sites

  • Assess how mutation of one modification site affects other modifications

  • For example, examine how ATF5(K29R) mutation affects phosphorylation at sites like Ser-92, Thr-94, Ser-126, and Ser-190

• Temporal analysis:

  • Conduct time-course experiments after stimulation with various signals

  • Monitor the sequence of different modifications to establish hierarchical relationships

  • Determine if acetylation precedes or follows other modifications like phosphorylation by NLK

• Modulator studies:

  • Test the effect of ubiquitination inhibitors on ATF5 acetylation status

  • Examine how cisplatin, which inhibits ubiquitination by blocking interaction with CDC34, affects acetylation levels

What are the methodological challenges in studying ATF5 acetylation in primary tissues versus cell lines?

Studying ATF5 acetylation in primary tissues presents several methodological challenges compared to cell lines:

Additional considerations for primary tissue analysis:

• Maintain tissue samples at cold temperatures throughout processing to preserve acetylation status

• Include deacetylase inhibitors in all extraction buffers

• Process tissues as quickly as possible after collection

• Consider using proximity ligation assays for enhanced detection sensitivity

How can researchers use Acetyl-ATF5 (K29) antibodies to study the role of ATF5 in disease models?

Researchers can leverage Acetyl-ATF5 (K29) antibodies to investigate ATF5's role in disease models through several sophisticated approaches:

• Cancer research applications:

  • Compare acetylation levels between tumor and adjacent normal tissues

  • Correlate acetylation status with disease progression, patient survival, and treatment response

  • Investigate how acetylated ATF5 regulates cancer-specific pathways by ChIP-seq analysis of promoter binding

  • Study how pharmacological interventions targeting p300 affect ATF5 acetylation and cancer cell survival

• Neural disease models:

  • Examine acetylated ATF5 levels in neurodegenerative disease models

  • Investigate how ATF5 acetylation affects olfactory sensory neuron survival and function

  • Study the role of acetylated ATF5 in cerebral cortex formation and neuroprogenitor cell proliferation

  • Analyze how pathological conditions alter ATF5 acetylation in neural tissues

• Viral infection studies:

  • Investigate how human cytomegalovirus (HCMV) IE86 protein induces ATF5 acetylation

  • Analyze how virus-induced ATF5 acetylation promotes cell survival during infection

  • Compare acetylation mechanisms between p300-dependent cellular pathways and virus-hijacked pathways

  • Develop inhibitors of virus-induced ATF5 acetylation as potential therapeutic strategies

• Methodological approach for disease models:

  • Use immunohistochemistry with Acetyl-ATF5 (K29) antibodies on tissue microarrays

  • Perform ChIP-seq to identify genome-wide binding sites of acetylated ATF5 in disease states

  • Conduct proteomics analysis to identify disease-specific interactors of acetylated ATF5

  • Employ CRISPR/Cas9 to generate disease models with ATF5(K29R) mutation to assess acetylation-dependent pathology

What are common issues when using Acetyl-ATF5 (K29) antibodies and how can they be resolved?

When working with Acetyl-ATF5 (K29) antibodies, researchers may encounter several technical challenges:

Additional optimization strategies:

• For challenging samples, consider immunoprecipitation with general ATF5 antibody followed by Western blotting with Acetyl-ATF5 (K29) antibody

• When working with tissues, extend the primary antibody incubation time to overnight at 4°C

• For ELISA applications, a high dilution (1:20000) is recommended to minimize background while maintaining specific signal

How can researchers optimize chromatin immunoprecipitation (ChIP) protocols for Acetyl-ATF5 (K29) antibody?

Optimizing ChIP protocols for Acetyl-ATF5 (K29) antibody requires careful consideration of several parameters:

• Crosslinking optimization:

  • Use dual crosslinking with 1.5 mM EGS (ethylene glycol bis[succinimidylsuccinate]) for 30 minutes followed by 1% formaldehyde for 10 minutes

  • This approach better preserves protein-protein interactions (ATF5-p300) as well as protein-DNA interactions

  • Quench with 125 mM glycine for 5 minutes

• Chromatin preparation:

  • Sonicate to achieve fragments of 200-500 bp

  • Include deacetylase inhibitors (5 mM sodium butyrate and 1 μM trichostatin A) in all buffers

  • Add protease inhibitors and phosphatase inhibitors to preserve all modifications

• Immunoprecipitation conditions:

  • Pre-clear chromatin with protein A/G beads

  • Use 5-10 μg of Acetyl-ATF5 (K29) antibody per ChIP reaction

  • Include IgG control, input control, and if possible, ChIP with ATF5(K29R) mutant-expressing cells as negative control

  • Extend incubation time to overnight at 4°C with gentle rotation

• Washing and elution:

  • Perform stringent washes (increasing salt concentrations)

  • Consider a two-step elution: first with acetylated peptide competition to ensure specificity, followed by standard SDS elution

  • Reverse crosslinking at 65°C for 6-8 hours

• Data analysis:

  • Design primers spanning known ATF5 binding sites (ARE regions) and potential target regions (like SRE)

  • Include primers for both known ATF5 targets (e.g., Egr-1 promoter) and non-target regions as controls

  • Normalize to input and IgG controls

How do environmental factors and experimental conditions affect ATF5 acetylation detection?

Various environmental factors and experimental conditions can significantly impact ATF5 acetylation detection:

• Cell culture conditions affecting acetylation levels:

  • Serum deprivation disrupts ATF5-p300 interaction and decreases acetylation

  • Cell density influences acetylation (confluent cultures may show different patterns)

  • Growth factor stimulation (e.g., EGF) enhances ATF5 acetylation through ERK/MAPK signaling

  • Cell stress conditions like staurosporine treatment interrupt the physical association between ATF5 and p300

• Sample preparation considerations:

  • Rapid processing is crucial as acetylation is dynamic and can be lost

  • Lysis buffer composition dramatically affects detection (include deacetylase inhibitors)

  • Temperature during processing (keep samples cold to preserve acetylation)

  • pH of buffers (maintain pH 7.5-8.0 for optimal antibody recognition)

• Detection method optimization:

  Condition	Impact on Detection	Optimization Strategy
  Fixation method	Crosslinking can mask epitopes	Use milder fixation; try epitope retrieval methods
  Blocking agent	BSA vs. milk can affect background	BSA (0.5%) is recommended for phospho-epitopes and acetyl-epitopes
  Buffer ionic strength	High salt can disrupt antibody binding	Maintain moderate ionic strength in washing buffers
  Incubation temperature	Cold temperatures preserve modifications	Perform antibody incubations at 4°C overnight
  Detergent concentration	Excessive detergent can reduce signal	Use 0.05-0.1% Tween-20 in washing buffers

• Special considerations for in vivo studies:

  • Time from sacrifice to tissue processing is critical (should be minimized)

  • Perfusion with deacetylase inhibitors prior to tissue collection

  • Flash freezing versus fixation (both have advantages and limitations)

  • Consider regional differences in acetylation status when analyzing brain or other heterogeneous tissues

How might single-cell analysis techniques advance our understanding of ATF5 acetylation dynamics?

Single-cell analysis techniques offer revolutionary approaches to understanding ATF5 acetylation dynamics:

• Single-cell proteomics approaches:

  • Mass cytometry (CyTOF) with metal-conjugated Acetyl-ATF5 (K29) antibodies allows simultaneous detection of acetylated ATF5 and other proteins/modifications

  • Single-cell Western blotting to detect heterogeneity in ATF5 acetylation within populations

  • Microfluidic antibody capture to quantify acetylated ATF5 levels in individual cells

• Imaging-based approaches:

  • Super-resolution microscopy with fluorescently labeled Acetyl-ATF5 (K29) antibodies for spatial localization

  • FRET-based sensors to monitor ATF5 acetylation in real-time in living cells

  • Proximity ligation assays to visualize interactions between acetylated ATF5 and binding partners like p300

• Single-cell genomics integration:

  • CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) to correlate ATF5 acetylation with transcriptional profiles

  • Single-cell CUT&Tag to map acetylated ATF5 genomic binding sites in individual cells

  • Combined single-cell RNA-seq and protein analysis to link acetylated ATF5 levels to target gene expression

• Advantages for understanding biological heterogeneity:

  • Reveal cell-to-cell variation in ATF5 acetylation status within tumors

  • Track temporal dynamics of acetylation during differentiation processes

  • Identify rare cell populations with unique ATF5 acetylation patterns that may have critical functional roles

What potential therapeutic applications could emerge from understanding ATF5 acetylation mechanisms?

Understanding ATF5 acetylation mechanisms could lead to several promising therapeutic approaches:

• Cancer therapy strategies:

  • Develop small molecules that specifically disrupt the interaction between acetylated ATF5 and p300

  • Design peptidomimetics that compete with ATF5 for p300 binding

  • Create selective inhibitors that block p300-mediated acetylation of ATF5 at K29

  • Target downstream pathways activated by acetylated ATF5, such as Egr-1 signaling

• Glioblastoma-specific applications:

  • Exploit the finding that ATF5 inhibition selectively kills glioblastoma cells but not surrounding normal cells

  • Develop targeted delivery systems for ATF5 acetylation inhibitors to cross the blood-brain barrier

  • Combine ATF5 acetylation inhibitors with standard glioblastoma treatments for synergistic effects

  • Screen for compounds that induce ATF5(K29R)-like phenotypes in glioblastoma cells

• Anti-viral therapeutic approaches:

  • Target the mechanism by which HCMV IE86 induces ATF5 acetylation

  • Develop compounds that prevent virus-induced ATF5 acetylation without affecting normal cellular functions

  • Create combination therapies targeting both viral proteins and host acetylation machinery

• Diagnostic and prognostic applications:

  • Develop Acetyl-ATF5 (K29) immunohistochemistry as a prognostic biomarker for cancer progression

  • Create liquid biopsy assays to detect circulating acetylated ATF5 as an early cancer biomarker

  • Use acetylated ATF5 levels to predict response to therapies targeting cell proliferation pathways

How might computational approaches and structural biology advance ATF5 acetylation research?

Computational approaches and structural biology offer powerful tools to advance ATF5 acetylation research:

• Structural characterization of acetylated ATF5:

  • Determine crystal structures of acetylated versus non-acetylated ATF5 to reveal conformational changes

  • Use NMR spectroscopy to analyze dynamic structural alterations induced by K29 acetylation

  • Perform molecular dynamics simulations to predict how acetylation affects protein flexibility and binding interfaces

  • Develop cryo-EM structures of the entire ATF5/p300 complex bound to DNA

• Computational prediction of acetylation effects:

  • Employ machine learning algorithms to predict additional acetylation sites on ATF5

  • Use molecular docking to identify potential small molecule inhibitors of the acetylated ATF5-p300 interaction

  • Apply systems biology approaches to model the broader network effects of ATF5 acetylation

  • Integrate multi-omics data to predict context-dependent outcomes of ATF5 acetylation

• Structure-based drug design applications:

  • Virtual screening of compound libraries against the acetyl-lysine binding pocket of p300

  • Fragment-based drug design targeting the interface between acetylated ATF5 and its binding partners

  • Development of structure-based peptidomimetics that mimic or block acetylated K29

  • Computational optimization of lead compounds for improved specificity and pharmacokinetic properties

• Data integration approaches:

  • Integrate ChIP-seq data with transcriptomic profiles to create comprehensive maps of acetylated ATF5 function

  • Apply network analysis to identify key nodes that connect acetylated ATF5 to broader cellular pathways

  • Develop predictive models of how perturbations to ATF5 acetylation affect multiple cellular processes

  • Use comparative genomics to identify evolutionary conservation of ATF5 acetylation mechanisms across species